Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Nephrology
Volume 2014 (2014), Article ID 854521, 6 pages
http://dx.doi.org/10.1155/2014/854521
Case Report

Amiloride as an Alternate Adjuvant Antiproteinuric Agent in Fabry Disease: The Potential Roles of Plasmin and uPAR

Nephrology Service, Hospital Británico de Buenos Aires, Perdriel 74, 1280 Buenos Aires, Argentina

Received 8 March 2014; Accepted 29 April 2014; Published 15 May 2014

Academic Editor: Alfons Segarra

Copyright © 2014 H. Trimarchi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Trimarchi, A. Karl, M. S. Raña et al., “Initially non-diagnosed Fabry’s disease when electronic microscopy is lacking: the continuing story of focal and segmental glomerulosclerosis,” Case Reports in Nephrology and Urology, vol. 3, pp. 51–57, 2013. View at Google Scholar
  2. R. J. Desnick, Y. Ioannou, and C. M. Eng, “α-Galactosidase A deficiency: Fabry disease,” in The Metabolic and Molecular Bases of Inherited Disease, C. R. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle, Eds., pp. 3733–3774, McGraw-Hill, New York, NY, USA, 2001. View at Google Scholar
  3. M. H. Branton, R. Schiffmann, S. G. Sabnis et al., “Natural history of fabry renal disease: influence of α-galactosidase a activity and genetic mutations on clinical course,” Medicine, vol. 81, no. 2, pp. 122–138, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. D. Tsakiris, H. K. Simpson, E. H. Jones et al., “Report on management of renal failure in Europe—XXVI, 1995. Rare diseases in renal replacement therapy in the ERA-EDTA Registry,” Nephrology Dialysis Transplantation, vol. 11, pp. 4–20, 1996. View at Google Scholar
  5. R. Thadhani, M. Wolf, M. L. West et al., “Patients with Fabry disease on dialysis in the United States,” Kidney International, vol. 61, no. 1, pp. 249–255, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Nakao, C. Kodama, T. Takenaka et al., “Fabry disease: detection of undiagnosed hemodialysis patients and identification of a “renal variant” phenotype,” Kidney International, vol. 64, no. 3, pp. 801–807, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. P. Kotanko, R. Kramar, D. Devrnja et al., “Results of a nationwide screening for Anderson-Fabry disease among dialysis patients,” Journal of the American Society of Nephrology, vol. 15, no. 5, pp. 1323–1329, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. C. M. Eng, N. Guffon, W. R. Wilcox et al., “Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry’s disease,” New England Journal of Medicine, vol. 345, pp. 9–16, 2001. View at Google Scholar
  9. R. Schiffmann, J. B. Kopp, H. A. Austin III et al., “Enzyme replacement therapy in fabry disease a randomized controlled trial,” Journal of the American Medical Association, vol. 285, no. 21, pp. 2743–2749, 2001. View at Google Scholar · View at Scopus
  10. A. Ortiz, J. P. Oliveira, S. Waldek, D. G. Warnock, B. Cianciaruso, and C. Wanner, “Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy,” Nephrology Dialysis Transplantation, vol. 23, no. 5, pp. 1600–1607, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. B. Najafian, E. Svarstad, L. Bostad et al., “Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease,” Kidney International, vol. 79, no. 6, pp. 663–670, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. D. de Zeeuw, “Albuminuria: a target for treatment of type 2 diabetic nephropathy,” Seminars in Nephrology, vol. 27, no. 2, pp. 172–181, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. J. C. Peterson, S. Adler, J. M. Burkart et al., “Blood pressure control, proteinuria, and the progression of renal disease: the modification of diet in renal disease study,” Annals of Internal Medicine, vol. 123, no. 10, pp. 754–762, 1995. View at Google Scholar · View at Scopus
  14. GISEN, “Randomized placebo-controlled trial effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy,” The Lancet, vol. 349, pp. 1857–1863, 1997. View at Google Scholar
  15. F. H. Wapstra, G. Navis, P. E. de Jong, and D. de Zeeuw, “Prognostic value of the short-term antiproteinuric response to ACE inhibition for prediction of GFR decline in patients with nondiabetic renal disease,” Experimental Nephrology, vol. 4, no. 1, pp. S47–S52, 1996. View at Google Scholar
  16. M. R. Lattanzio and M. R. Weir, “Have we fallen off target with concerns surrounding dual RAAS blockade,” Kidney International, vol. 78, no. 6, pp. 539–545, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. D. de Zeeuw, G. Remuzzi, H.-H. Parving et al., “Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL,” Kidney International, vol. 65, no. 6, pp. 2309–2320, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Abbate, C. Zoja, and G. Remuzzi, “How does proteinuria cause progressive renal damage?” Journal of the American Society of Nephrology, vol. 17, no. 11, pp. 2974–2984, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. M. R. Patel, F. Cecchi, M. Cizmarik et al., “Cardiovascular events in patients with Fabry disease: natural history data from the Fabry Registry,” Journal of the American College of Cardiology, vol. 57, no. 9, pp. 1093–1099, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. B. Pierre-Louis, A. Kumar, and W. H. Frishman, “Fabry disease: cardiac manifestations and therapeutic options,” Cardiology in Review, vol. 17, no. 1, pp. 31–35, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. F. Weidemann, A. Linhart, L. Monserrat, and J. Strotmann, “Cardiac challenges in patients with Fabry disease,” International Journal of Cardiology, vol. 141, no. 1, pp. 3–10, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. F. Weidemann, J. M. Strotmann, M. Niemann et al., “Heart valve involvement in Fabry cardiomyopathy,” Ultrasound in Medicine and Biology, vol. 35, no. 5, pp. 730–735, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. R. Schiffmann, D. G. Warnock, M. Banikazemi et al., “Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy,” Nephrology Dialysis Transplantation, vol. 24, no. 7, pp. 2102–2111, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. W. R. Wilcox, J. P. Oliveira, R. J. Hopkin et al., “Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry,” Molecular Genetics and Metabolism, vol. 93, no. 2, pp. 112–128, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. J. S. Shah, D. A. Hughes, B. Sachdev et al., “Prevalence and clinical significance of cardiac arrhythmia in Anderson-Dabry disease,” American Journal of Cardiology, vol. 96, no. 6, pp. 842–846, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. P. Stenvinkel, “Endothelial dysfunction and inflammation—is there a link?” Nephrology Dialysis Transplantation, vol. 16, no. 10, pp. 1968–1971, 2001. View at Google Scholar · View at Scopus
  27. A. Festa, J. D'Agostino R., G. Howard, L. Mykkanen, R. P. Tracy, and S. M. Haffner, “Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects. The Insulin Resistance Atherosclerosis Study,” Kidney International, vol. 58, no. 4, pp. 1703–1710, 2000. View at Publisher · View at Google Scholar · View at Scopus
  28. A. H. J. Salmon, J. K. Ferguson, and J. L. Burford, “Loss of the endothelial glycocalyx links albuminuria and vascular dysfunction,” Journal of the American Society of Nephrology, vol. 23, pp. 1339–1350, 2012. View at Google Scholar
  29. B. Zhang, S. Xie, W. Shi, and Y. Yang, “Amiloride off-target effect inhibits podocyte urokinase receptor expression and reduces proteinuria,” Nephrology Dialysis Transplantation, vol. 27, pp. 1746–1755, 2012. View at Google Scholar
  30. C. Wei, C. C. Möller, M. M. Altintas et al., “Modification of kidney barrier function by the urokinase receptor,” Nature Medicine, vol. 14, no. 1, pp. 55–63, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. C. Wei, S. El Hindi, J. Li et al., “Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis,” Nature Medicine, vol. 17, no. 8, pp. 952–960, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. H. Trimarchi, “Primary focal and segmental glomerulosclerosis and suPAR: where do we stand and where are we heading to?” World Journal of Nephrology, vol. 2, pp. 103–110, 2013. View at Google Scholar
  33. K. Utsumi, K. Itoh, R. Kase et al., “Urinary excretion of the vitronectin receptor (integrin α(V)β3) in patients with Fabry disease,” Clinica Chimica Acta, vol. 279, no. 1-2, pp. 55–68, 1999. View at Publisher · View at Google Scholar · View at Scopus
  34. B. Krueger, J. Stubbe, O. N. Jensen et al., “Plasmin in nephrotic urine activates the epithelial sodium channel,” Journal of the American Society of Nephrology, vol. 20, pp. 299–310, 2009. View at Google Scholar
  35. N. D. Vaziri, E. C. Gonzales, B. Shayestehfar, and C. H. Barton, “Plasma levels and urinary excretion of fibrinolytic and protease inhibitory proteins in nephrotic syndrome,” Journal of Laboratory and Clinical Medicine, vol. 124, no. 1, pp. 118–124, 1994. View at Google Scholar · View at Scopus
  36. C. J. Passero, G. M. Mueller, H. Rondon-Berrios, S. P. Tofovic, R. P. Hughey, and T. R. Kleyman, “Plasmin activates epithelial Na+ channels by cleaving the γ subunit,” Journal of Biological Chemistry, vol. 283, no. 52, pp. 36586–36591, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. J. Reiser, “Role of soluble uPAR in the pathogenesis of proteinuric kidney disease,” US Patent Application Publication. Pub. No.: US 2011/0212083 A1, 2011.
  38. D. F. Moore, O. V. Krokhin, R. C. Beavis et al., “Proteomics of specific treatment-related alterations in Fabry disease: a strategy to identify biological abnormalities,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 8, pp. 2873–2878, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. L. A. Miles, C. M. Dahlberg, E. G. Levin, and E. F. Plow, “Gangliosides interact directly with plasminogen and urokinase and may mediate binding of these fibrinolytic components to cells,” Biochemistry, vol. 28, no. 24, pp. 9337–9343, 1989. View at Publisher · View at Google Scholar · View at Scopus
  40. J. Pereira, B. Boyd, J. Newbigging, C. Lingwood, and P. M. Strasberg, “Increased globotriaosylceramide on plasma membranes of synchronized familial dysautonomia cells—verotoxin binding studies,” Journal of Molecular Neuroscience, vol. 5, no. 2, pp. 121–132, 1994. View at Publisher · View at Google Scholar · View at Scopus